Avior Wealth Management’s MaxCyte MXCT Stock Holding History

Avior Wealth Management’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-17	Closed	-$71	–	3166
2024 Q1	$71	Buy	+17	New	+$80	﹤0.01%	3339

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avior Wealth Management's MXCT Position: Q2 2024 in Review

Avior Wealth Management sold out of MaxCyte (MXCT) in Q2 2024, closing a stake of 17 shares — an estimated $71 sold.

Avior Wealth Management first reported a position in MXCT in Q1 2024 and held it in 1 quarter. The position peaked at $71 in Q1 2024. 114 funds tracked by Wall St. Rank hold MXCT as of Q2 2024.

Avior Wealth Management reported no remaining MaxCyte position as of Q2 2024 after selling out during the quarter.
Avior Wealth Management sold 17 MaxCyte shares in Q2 2024, an estimated $71.
Avior Wealth Management first reported a position in MaxCyte in Q1 2024 and held it in 1 quarter.
Avior Wealth Management's MaxCyte position peaked at $71 in Q1 2024.
114 funds tracked by Wall St. Rank held MaxCyte as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.